“…A major outstanding issue that is hampering the development of cordycepin as a lead compound is the lack of a clearly identified cordycepin-binding target molecule and a mechanism of action that connects this binding with the therapeutic effects. Proposed binding targets include poly (A) polymerases, adenosine receptors, CDK2, PARP1, AKT, AMPK, FGFR2 and RuvB-like ATPase 2 (RUVBL2) [ 31 , 32 , 35 , 40 , 65 , 66 , 106 , 145 , 155 , 167 , 201 , 210 , 239 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 278 ]. A recent careful evaluation of AMPK as a cordycepin target concluded that although it is bound and activated by cordycepin monophosphate, AMPK activation is not responsible for the effects of cordycepin on cell survival [ 166 ].…”